276 related articles for article (PubMed ID: 18295442)
21. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
22. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
23. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient.
Bonvalot S; Rimareix F; Causeret S; Le Péchoux C; Boulet B; Terrier P; Le Cesne A; Muret J
Ann Surg Oncol; 2009 Dec; 16(12):3350-7. PubMed ID: 19830495
[TBL] [Abstract][Full Text] [Related]
24. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
25. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
26. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
[TBL] [Abstract][Full Text] [Related]
27. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
Hill S; Thomas JM
Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
[TBL] [Abstract][Full Text] [Related]
28. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
[TBL] [Abstract][Full Text] [Related]
29. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
30. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
31. Liposomal doxorubicin with and without TNFalpha in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results.
Di Filippo F; Anzà M; Garinei R; Cavaliere F; Perri P; Botti C; Di Angelo P; Di Filippo S; Maini CL; Pasqualoni R; Di Segni S; Colantonio S; Bruno P; Piarulli L; Principi F
In Vivo; 2006; 20(6A):735-8. PubMed ID: 17203757
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912
[TBL] [Abstract][Full Text] [Related]
33. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
34. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas.
Hegazy MA; Kotb SZ; Sakr H; El Dosoky E; Amer T; Hegazi RA; Farouk O
Ann Surg Oncol; 2007 Feb; 14(2):568-76. PubMed ID: 17094027
[TBL] [Abstract][Full Text] [Related]
35. Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
Moncrieff MD; Kroon HM; Kam PC; Stalley PD; Scolyer RA; Thompson JF
Ann Surg Oncol; 2008 Oct; 15(10):2749-56. PubMed ID: 18648882
[TBL] [Abstract][Full Text] [Related]
36. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.
Grabellus F; Kraft C; Sheu SY; Ebeling P; Bauer S; Lendemans S; Schmid KW; Taeger G
Ann Surg Oncol; 2009 Mar; 16(3):676-86. PubMed ID: 19130134
[TBL] [Abstract][Full Text] [Related]
38. Isolated limb perfusion: what is the evidence for its use?
Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BB
Ann Surg Oncol; 2004 Sep; 11(9):837-45. PubMed ID: 15313738
[TBL] [Abstract][Full Text] [Related]
39. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
40. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]